Related Interviews

Aggressive Growth Strategy Targets Disruptive Companies and Themes
May 07, 2024
Tauber, Jason

Obesity Drugmakers Still a ‘Buy’ Despite Lofty Valuations
April 18, 2024
Baum, Andrew

Two Deeply Discounted Biotechs Offer Innovative COVID Treatments
November 12, 2023
Brozak, Steve

Gene Editing Companies Enjoy Momentum While Gene Therapies Lag
September 30, 2021
Livshits, Geulah

D.C. Drug Price Debate Creates Opportunity for Longer-Term Pharma Investors
September 30, 2021
Kedra, Kevin

Long-term Investment Strategy Uses Short Selling to Augment Holdings
July 01, 2021
Parnes, Joseph

Small-Cap Fund Examines ESG Practices, Five-Year Track Record
April 09, 2021
Williams, Richard Q.

AI-Powered ETF Works with IBM Watson to Analyze Market Data
April 05, 2021
Natividad, Chris

Technology-Backed Biotech Companies Promise Long-Term Payoffs
March 18, 2021
Vandermosten, John

COVID Vaccines in Pipeline Promise Effective Protection Against Variants
March 18, 2021
Raja, Kumaraguru

Looking for Stocks That Pay a Good Yield
November 20, 2020
Powell, Gregory

Midcap and Small-Cap Biopharma Opportunities a Better Way to Go in 2021
September 30, 2020
Singh, Hartaj

Pharma M&A Activity Expected to Return in 2021
September 21, 2020
Kedra, Kevin

Using an Exchange-Traded Fund to Invest in Infectious Disease
September 04, 2020
Masucci, Samuel, Panettieri Jr., Reynold A.

Looking Toward the Downtrodden Infectious Space for Opportunities
March 20, 2020
Brozak, Steve

Clinical Data and M&A Serve as Catalysts in 2019
March 22, 2019
Roy, Soumit

The First Half of 2019 Expected to Be Rough for the Biotech Sector
March 15, 2019
Singh, Hartaj